Click for best price
Postpemic Era Biosimilars Treatment Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
(Post-pandemic Era)-Global Biosimilars Treatment Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Biosimilars Treatment industry at home and abroad, estimate the overall market scale of the Biosimilars Treatment industry and the market share of major countries, Biosimilars Treatment industry, and study and judge the downstream market demand of Biosimilars Treatment through systematic research, Analyze the competition pattern of Biosimilars Treatment, so as to help solve the pain points of various stakeholders in Biosimilars Treatment industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Biosimilars Treatment Market by Research Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Biosimilars Treatment Market?
Bayer
Eli Lily, Inc.
Pfizer, Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Amgen Inc.
Biocon
Dr. Reddy?s Laboratories
Roche Ltd.
Celltrion, Inc.
Samsung Bioepis
Major Type of Biosimilars Treatment Covered in Research report:
Recombinant Non ? Glycosylated Proteins
Recombinant Glycosylated Proteins
Recombinant Peptides
Application Segments Covered in Research Market
Oncology
Chronic and Autoimmune Disease
Blood Disorders
Growth Hormone Disease
Infectious Disease
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Biosimilars Treatment Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
92 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Biosimilars Treatment Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Biosimilars Treatment Market by Value
2.2.1 Global Biosimilars Treatment Revenue by Type
2.2.2 Global Biosimilars Treatment Market by Value
2.3 Global Biosimilars Treatment Market by Sales
2.3.1 Global Biosimilars Treatment Sales by Type
2.3.2 Global Biosimilars Treatment Market by Sales
3. The Major Driver of Biosimilars Treatment Industry
3.1 Historical & Forecast Global Biosimilars Treatment Sales and Revenue (2018-2028)
3.2 Largest Application for Biosimilars Treatment (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Biosimilars Treatment Market
4.1 Regional Market Size in Terms of Sales (2022 & 2028)
4.2 Regional Market Share in Terms of Revenue (2022 & 2028)
4.3 Concentration Ratio (CR5& CR10) of Biosimilars Treatment Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Biosimilars Treatment Sales (2018-2028)
5.1 Current and Estimated Sales Breakdown by Type (2018-2028)
5.2 Current and Estimated Sales Breakdown by Application (2018-2028)
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Biosimilars Treatment Sales (2018-2028)
6.1 Current and Estimated Sales Breakdown by Type (2018-2028)
6.2 Current and Estimated Sales Breakdown by Application (2018-2028)
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Biosimilars Treatment Sales (2018-2028)
7.1 Current and Estimated Sales Breakdown by Type (2018-2028)
7.2 Current and Estimated Sales Breakdown by Application (2018-2028)
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Biosimilars Treatment Sales (2018-2028)
8.1 Current and Estimated Sales Breakdown by Type (2018-2028)
8.2 Current and Estimated Sales Breakdown by Application (2018-2028)
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Biosimilars Treatment Sales (2018-2028)
9.1 Current and Estimated Sales Breakdown by Type (2018-2028)
9.2 Current and Estimated Sales Breakdown by Application (2018-2028)
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Biosimilars Treatment Sales (2018-2028)
10.1 Current and Estimated Sales Breakdown by Type (2018-2028)
10.2 Current and Estimated Sales Breakdown by Application (2018-2028)
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Biosimilars Treatment Sales (2018-2028)
11.1 Current and Estimated Sales Breakdown by Type (2018-2028)
11.2 Current and Estimated Sales Breakdown by Application (2018-2028)
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. South America Biosimilars Treatment Sales (2018-2028)
12.1 Current and Estimated Sales Breakdown by Type (2018-2028)
12.2 Current and Estimated Sales Breakdown by Application (2018-2028)
12.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
12.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
13. Global Biosimilars Treatment Average Price Trend
13.1 Market Price for Each Type of Biosimilars Treatment in US (2018-2022)
13.2 Market Price for Each Type of Biosimilars Treatment in Europe (2018-2022)
13.3 Market Price for Each Type of Biosimilars Treatment in China (2018-2022)
13.4 Market Price for Each Type of Biosimilars Treatment in Japan (2018-2022)
13.5 Market Price for Each Type of Biosimilars Treatment in India (2018-2022)
13.6 Market Price for Each Type of Biosimilars Treatment in Korea (2018-2022)
13.7 Market Price for Each Type of Biosimilars Treatment in Southeast Asia (2018-2022)
13.8 Market Price for Each Type of Biosimilars Treatment in South America (2018-2022)
14. Industrial Chain (Impact of COVID-19)
14.1 Biosimilars Treatment Industrial Chain Analysis
14.2 Downstream
14.3 Impact of COVID-19
14.4 Post-pandemic Era
14.5 Technology Trends of Biosimilars Treatment
15. Biosimilars Treatment Competitive Landscape
15.1 Bayer
15.1.1 Bayer Company Profiles
15.1.2 Bayer Product Introduction
15.1.3 Bayer Biosimilars Treatment Sales, Revenue (2018-2022)
15.1.4 Strategic initiatives
15.2 Eli Lily, Inc.
15.2.1 Eli Lily, Inc. Company Profiles
15.2.2 Eli Lily, Inc. Product Introduction
15.2.3 Eli Lily, Inc. Biosimilars Treatment Sales, Revenue (2018-2022)
15.2.4 Strategic initiatives
15.3 Pfizer, Inc.
15.3.1 Pfizer, Inc. Company Profiles
15.3.2 Pfizer, Inc. Product Introduction
15.3.3 Pfizer, Inc. Biosimilars Treatment Sales, Revenue (2018-2022)
15.3.4 Strategic initiatives
15.4 Sandoz International GmbH
15.4.1 Sandoz International GmbH Company Profiles
15.4.2 Sandoz International GmbH Product Introduction
15.4.3 Sandoz International GmbH Biosimilars Treatment Sales, Revenue (2018-2022)
15.4.4 Strategic initiatives
15.5 Teva Pharmaceutical Industries Limited
15.5.1 Teva Pharmaceutical Industries Limited Company Profiles
15.5.2 Teva Pharmaceutical Industries Limited Product Introduction
15.5.3 Teva Pharmaceutical Industries Limited Biosimilars Treatment Sales, Revenue (2018-2022)
15.5.4 Strategic initiatives
15.6 Amgen Inc.
15.6.1 Amgen Inc. Company Profiles
15.6.2 Amgen Inc. Product Introduction
15.6.3 Amgen Inc. Biosimilars Treatment Sales, Revenue (2018-2022)
15.6.4 Strategic initiatives
15.7 Biocon
15.7.1 Biocon Company Profiles
15.7.2 Biocon Product Introduction
15.7.3 Biocon Biosimilars Treatment Sales, Revenue (2018-2022)
15.7.4 Strategic initiatives
15.8 Dr. Reddy?s Laboratories
15.8.1 Dr. Reddy?s Laboratories Company Profiles
15.8.2 Dr. Reddy?s Laboratories Product Introduction
15.8.3 Dr. Reddy?s Laboratories Biosimilars Treatment Sales, Revenue (2018-2022)
15.8.4 Strategic initiatives
15.9 Roche Ltd.
15.9.1 Roche Ltd. Company Profiles
15.9.2 Roche Ltd. Product Introduction
15.9.3 Roche Ltd. Biosimilars Treatment Sales, Revenue (2018-2022)
15.9.4 Strategic initiatives
15.10 Celltrion, Inc.
15.10.1 Celltrion, Inc. Company Profiles
15.10.2 Celltrion, Inc. Product Introduction
15.10.3 Celltrion, Inc. Biosimilars Treatment Sales, Revenue (2018-2022)
15.10.4 Strategic initiatives
15.11 Samsung Bioepis
16. Conclusion
17. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Sales by Application of Biosimilars Treatment Industry (Volume)
Figure 2. Biosimilars Treatment Sales by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2028)
Figure 4. The Top 10 and 5 Players Market Share by Biosimilars Treatment Revenue in 2022
Figure 5. US Biosimilars Treatment Sales (2018-2028)
Figure 6. Sales Breakdown by Type (%)
Figure 7. Sales Breakdown by Type (%)
Figure 8. Sales Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Biosimilars Treatment Sales (2018-2028)
Figure 12. Sales Breakdown by Type (%)
Figure 13. Sales Breakdown by Type (%)
Figure 14. Sales Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Biosimilars Treatment Sales (2018-2028)
Figure 18. Sales Breakdown by Type (%)
Figure 19. Sales Breakdown by Type (%)
Figure 20. Sales Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Biosimilars Treatment Sales (2018-2028)
Figure 25. Sales Breakdown by Type (%)
Figure 26. Sales Breakdown by Type (%)
Figure 27. Sales Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Biosimilars Treatment Sales (2018-2028)
Figure 31. Sales Breakdown by Type (%)
Figure 32. Sales Breakdown by Type (%)
Figure 33. Sales Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Biosimilars Treatment Sales (2018-2028)
Figure 37. Sales Breakdown by Type (%)
Figure 38. Sales Breakdown by Type (%)
Figure 39. Sales Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Biosimilars Treatment Sales (2018-2028)
Figure 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Figure 44. Sales Breakdown by Type (%)
Figure 45. Sales Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Biosimilars Treatment Revenue, by Type (Million USD) (2018-2028)
Table 4. Biosimilars Treatment Sales, by Type (K Unit) (2018-2028)
Table 5. Biosimilars Treatment Sales (K Unit) by Application (2018-2028)
Table 6. Biosimilars Treatment Sales (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Sales (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2028)
Table 10. Ranking of Global Top Biosimilars Treatment Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Biosimilars Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 13. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 14. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 15. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Biosimilars Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 19. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 20. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 21. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Biosimilars Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 25. Table Current and Estimated Sales Breakdown by Type
Table 26. Current and Estimated Sales Breakdown by Type
Table 27. Current and Estimated Sales Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Biosimilars Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 30. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 31. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 32. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Biosimilars Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 36. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 37. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 38. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Biosimilars Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 42. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 44. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Biosimilars Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 48. Table Current and Estimated Sales Breakdown by Type (2018-2028)
Table 49. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Biosimilars Treatment in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Biosimilars Treatment in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Biosimilars Treatment in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Biosimilars Treatment in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Biosimilars Treatment in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Biosimilars Treatment in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Biosimilars Treatment in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Bayer Profiles
Table 61. Bayer Biosimilars Treatment Product Introduction
Table 62. Bayer Biosimilars Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Bayer Strategic initiatives
Table 64. Eli Lily, Inc. Profiles
Table 65. Eli Lily, Inc. Biosimilars Treatment Product Introduction
Table 66. Eli Lily, Inc. Biosimilars Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Eli Lily, Inc. Strategic initiatives
Table 68. Pfizer, Inc. Profiles
Table 69. Pfizer, Inc. Biosimilars Treatment Product Introduction
Table 70. Pfizer, Inc. Biosimilars Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Pfizer, Inc. Strategic initiatives
Table 72. Sandoz International GmbH Profiles
Table 73. Sandoz International GmbH Biosimilars Treatment Product Introduction
Table 74. Sandoz International GmbH Biosimilars Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Sandoz International GmbH Strategic initiatives
Table 76. Teva Pharmaceutical Industries Limited Profiles
Table 77. Teva Pharmaceutical Industries Limited Biosimilars Treatment Product Introduction
Table 78. Teva Pharmaceutical Industries Limited Biosimilars Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Teva Pharmaceutical Industries Limited Strategic initiatives
Table 80. Amgen Inc. Profiles
Table 81. Amgen Inc. Biosimilars Treatment Product Introduction
Table 82. Amgen Inc. Biosimilars Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Amgen Inc. Strategic initiatives
Table 84. Biocon Profiles
Table 85. Biocon Biosimilars Treatment Product Introduction
Table 86. Biocon Biosimilars Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Biocon Strategic initiatives
Table 88. Dr. Reddy?s Laboratories Profiles
Table 89. Dr. Reddy?s Laboratories Biosimilars Treatment Product Introduction
Table 90. Dr. Reddy?s Laboratories Biosimilars Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Dr. Reddy?s Laboratories Strategic initiatives
Table 92. Roche Ltd. Profiles
Table 93. Roche Ltd. Biosimilars Treatment Product Introduction
Table 94. Roche Ltd. Biosimilars Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. Roche Ltd. Strategic initiatives
Table 97. Celltrion, Inc. Profiles
Table 98. Celltrion, Inc. Biosimilars Treatment Product Introduction
Table 99. Celltrion, Inc. Biosimilars Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. Celltrion, Inc. Strategic initiatives
Table 101. Samsung Bioepis Profiles
Table 102. Samsung Bioepis Biosimilars Treatment Product Introduction
Table 103. Samsung Bioepis Biosimilars Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 104. Samsung Bioepis Strategic initiatives
